Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients

Lymphedema of Leg Clinical Trial

— ACTIODERM  

Official title:

Physiological Study to Assess Mechanism of Action of MOBIDERM® in Lower-limb Lymphedema Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04252690
• Other study ID #: EC18
• Secondary ID: ANSM
• Status: Completed
• Phase: N/A
• Start date: July 1, 2020
• Est. completion date: June 23, 2022

Study information

• Verified date: April 2023
• Source: Thuasne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

MOBIDERM® demonstrated his interest through clinical studies on the treatment of lower or upper limb lymphedema (Mestre et al 2017; Quéré et al. 2014). This CE (Conformity European)-marking device is well established both in ambulatory and hospitalisation. Nevertheless, the mechanism of action of this device had never been confirmed and no experimental clinical studies had been performed. The hypothesis is that the MOBIDERM system creates a pressure differential between the contact zone underneath the foam cubes composing the system and their surrounding area, leading to a shear effect on the subcutaneous tissues treated. The aim of this study is thus to assess the mechanism of action of MOBIDERM on the lymphatic system by evaluating quantitative and qualitative effects of this medical device on lymphatic system, oedema volume and cutaneous parameters in 10 lymphoedema patients during their hospitalisation for reduction phase.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: June 23, 2022
• Est. primary completion date: June 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Primary or secondary lower limb lymphedema of stage 2 or 3 according to the criteria defined by International Society of Lymphology
• Affected leg that fits with one of the standard sizes of the Auto-Adjustable MOBIDERM® Autofit stocking provided
• Signed informed consent prior to any study-mandated procedure.

Exclusion Criteria:

• Pregnant or breastfeeding patient
• Childbearing age patient without contraception
• Intolerance to Mobiderm or known allergy to the components used
• Evolutive lower limb infection
• Acute lower limb inflammation
• Dermatological ailment oozing from the treated limb
• Severe medical condition that may interfere with the proper conduct of the study
• Advanced diabetic microangiopathy
• Limb arteritis stage III or IV
• Decompensated heart failure
• Involvement in another clinical study
• Patient mentally incapable of understanding the nature, objectives and possible consequences of the study and / or refusing to submit to the constraints of this trial

Related Conditions & MeSH terms

• Lymphedema
• Lymphedema Congenital
• Lymphedema of Leg
• Lymphedema Primary
• Lymphedema, Secondary

Intervention

Device:
• MOBIDERM® autofit : auto-adjustable compression stocking
The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization). Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics). Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually. Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey).

Locations

Country	Name	City	State
France	CHRU Tours	Tours

Sponsors (3)

Lead Sponsor	Collaborator
Thuasne	Delta Consultants, University Hospital, Tours

Country where clinical trial is conducted

France, 

References & Publications (2)

Mestre S, Calais C, Gaillard G, Nou M, Pasqualini M, Ben Amor C, Quere I. Interest of an auto-adjustable nighttime compression sleeve (MOBIDERM(R) Autofit) in maintenance phase of upper limb lymphedema: the MARILYN pilot RCT. Support Care Cancer. 2017 Aug;25(8):2455-2462. doi: 10.1007/s00520-017-3652-5. Epub 2017 Mar 9. — View Citation

Quere I, Presles E, Coupe M, Vignes S, Vaillant L, Eveno D, Laporte S, Leizorovicz A; POLIT Study investigators. Prospective multicentre observational study of lymphedema therapy: POLIT study. J Mal Vasc. 2014 Jul;39(4):256-63. doi: 10.1016/j.jmv.2014.05.004. Epub 2014 Jun 12. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline extraction rates at 3 days after wearing MOBIDERM	Assess the difference of extraction rate (%) in different areas (ankle, upper and lower middle third of the leg, knee, calf) by lymphoscintigraphy performed at D1 and D3 after wearing MOBIDERM®	Day : 3
Secondary	Change of vascular lymphatic activity between D1 and D3	Assess change of vascular lymphatic activity based on qualitative data (activity YES/NO ; quality of activity : usual - semi usual - unusual) obtained during dynamic acquisition of lymphoscintigraphy from baseline to D3	Day : 3
Secondary	Change of lymphatic vascular flow between D1 and D3	Assess change of amplitude vascular flow : important - medium- weak ; and of flow velocity : normal, slow, inexistent from baseline to D3	Day : 3
Secondary	Change on lymphatic system between D1 and D3 : short term effect	Assess change on lymphatic system from baseline to D3 (short term effect) , based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.	Day : 3
Secondary	Change on lymphatic system between H2 and H4 : immediate effect	Assess change on lymphatic system from baseline to 2 and 4 hours : immediate effect, based on quantitative data : number of lympho node fixation ; and qualitative data: lympho node fixation intensity : important - medium - low ; tortuous appearance of the lymphatic vessels : YES/NO ; presence of collateral : YES/NO ; presence of dermal reflux : YES/NO ; presence of popliteal ganglion : YES/NO.	Hours : 2 and 4
Secondary	Lymphedema volume reduction between D1 and D3	Leg perimeters (cm) of 7 part of leg will be measured (ankle, patella, +10cm +20cm +30cm and -10cm -20cm and -30cm of patella). Based on truncated cone formula, volume (mL) of each leg will be calculated. These volumes will be compared between D1 and D3 in order to assess lymphedema volume reduction.	Days : 1 and 3
Secondary	Skin condition evolution between D1 and D3	Skin condition will be assessed by cutaneous ultrasound scan (skin thickness (mm) , skin echogenicity (hypoechogenicity - isoechogenicity, hyperechogenicity) , oedema distribution in the dermis (superficial dermis - deep dermis - overall of dermis -hypodermis and dermis) performed on 3 areas : ankle, leg and thigh. Skin condition evolution will be assessed at D1 and D3.	Days : 1 and 3
Secondary	Cutaneous suppleness between D1 and D3	Cutaneous suppleness evolution is assessed with a cutometer. Cutaneous suppleness is described by skin elasticity, elastic capacity and viscoelasticity. Cutometer measurements are expressed in millimetre (skin deformation, skin relaxation, skin extensibility) and will be presented as quantitative data.	Days : 1 and 3
Secondary	Number of type of serious and non-serious Adverse Device Effects	Number and type of serious and non-serious Adverse Device Effects (ADE) will be reported during the study	Day : 3
Secondary	Satisfaction regarding MOBIDERM	Satisfaction is measured by a satisfaction questionnaire wrote specifically for the study. This questionnaire is focused on positioning the product, comfort, esthetic and global satisfaction.	Day : 3